Patents by Inventor Marco Tartaglia
Marco Tartaglia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192765Abstract: The present invention relates to a peptide having the sequence from N-terminus to C-terminus X-2X-1ZX1X2X3X4X5 wherein Z is tyrosine, phosphotyrosine or a non-natural analogue of phosphotyrosine, such as phosphonodifluoromethyl phenylalanine (F2Pmp) X-2 is a hydrophobic amino acid, such as Leu, Ile, Val, Phe, Tyr, Trp and Met X-1 is any amino acid X1 is a hydrophobic amino acid, such as Ile, Leu, Val, Phe, Tyr, Trp and Met X3 is a hydrophobic amino acid, such as Leu, Ile, Val, Phe, Tyr, Trp and Met X5 is a hydrophobic amino acid, such as Trp, Ile, Val, Phe, Tyr, and Met X2 and X4 are anionic amino acids, preferably each independently is Asp or Glu. The peptide inhibits protein-protein interactions of the Src homology 2 domain-containing phosphatase 2 (SHP2), for the treatment of cancer and RASopathies and as a biomedical research tool.Type: ApplicationFiled: March 5, 2021Publication date: June 22, 2023Applicants: UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA", OSPEDALE PEDIATRICO BAMBINO GESÙInventors: Lorenzo STELLA, Barbara BIONDI, Gianfranco BOCCHINFUSO, Simone MARTINELLI, Marco TARTAGLIA
-
Publication number: 20150017649Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAFl or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.Type: ApplicationFiled: June 20, 2014Publication date: January 15, 2015Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOUNT SINAI SCHOOL OF MEDICINEInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio
-
Patent number: 8808992Abstract: The present invention is directed to methods of diagnosing Noonan-like syndrome with loose anagen hair comprising detecting a mutation in SHOC2 gene. One specific diagnostic mutation disclosed is an A-to-G transition at position 4 resulting in a mutation at position 2 of SHOC2 amino acid sequence from serine to glycine. The invention also provides related sequences and kits.Type: GrantFiled: May 6, 2010Date of Patent: August 19, 2014Assignees: Icahn School of Medicine at Mount Sinai, The Regents of the University of CaliforniaInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio, Ravi Iyengar, Avi Ma'ayan
-
Publication number: 20130029332Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gen RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.Type: ApplicationFiled: June 20, 2012Publication date: January 31, 2013Applicants: The Regents of the University of California, Mount Sinai School of MedicineInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio
-
Patent number: 8221979Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.Type: GrantFiled: November 16, 2007Date of Patent: July 17, 2012Assignees: Mount Sinai School of Medicine, The Regents of the University of CaliforniaInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio
-
Publication number: 20110059851Abstract: The present invention is directed to methods of diagnosing Noonan-like syndrome with loose anagen hair comprising detecting a mutation in SHOC2 gene. One specific diagnostic mutation disclosed is an A-to-G transition at position 4 resulting in a mutation at position 2 of SHOC2 amino acid sequence from serine to glycine. The invention also provides related sequences and kits.Type: ApplicationFiled: May 6, 2010Publication date: March 10, 2011Applicant: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: BRUCE D. GELB, MARCO TARTAGLIA, LEN PENNACCHIO, SRINIVAS RAVI IYENGAR, AVI MA'AYAN
-
Publication number: 20100009361Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants.Type: ApplicationFiled: November 16, 2007Publication date: January 14, 2010Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERS, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bruce D. Gelb, Marco Tartaglia, Len Pennacchio
-
Patent number: 7550262Abstract: Diagnostic and therapeutic applications for certain types of cancer and precancerous conditions, including those deriving from hematologic cells, are described. Of particular interest are those cancers and precancerous conditions associated with increased signaling in the RAS-MAP kinase pathway. The diagnostic and therapeutic applications described herein are based on certain mutations in the protein tyrosine phosphatase gene PTPN11 and its expression product, PTPN11, promoting a gain-of-function in PTPN11 activity. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and PTPN11 variants, and cells expressing such variants.Type: GrantFiled: November 5, 2003Date of Patent: June 23, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Bruce D. Gelb, Marco Tartaglia, Charlotte Niemeyer
-
Patent number: 7335469Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in the protein tyrosine phosphatase gene PTPN11 and its expression product, PTPN11, as well as mutations in other components in a PTPN11 signal transduction pathway promoting an increased signaling flux. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and PTPN11 variants, and cells expressing such variants.Type: GrantFiled: October 1, 2002Date of Patent: February 26, 2008Assignee: Mt. Sinai School of Medicine of New York UniversityInventors: Bruce D. Gelb, Marco Tartaglia
-
Publication number: 20040121384Abstract: Diagnostic and therapeutic applications for certain types of cancer and precancerous conditions, including those deriving from hematologic cells, are described. Of particular interest are those cancers and precancerous conditions associated with increased signaling in the RAS-MAP kinase pathway. The diagnostic and therapeutic applications described herein are based on certain mutations in the protein tyrosine phosphatase gene PTPN11 and its expression product, PTPN11, promoting a gain-of-function in PTPN11 activity. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and PTPN11 variants, and cells expressing such variants.Type: ApplicationFiled: November 5, 2003Publication date: June 24, 2004Applicants: Mount Sinai School of Medicine of New York University, Universitaetsklinikum FreiburgInventors: Bruce D. Gelb, Marco Tartaglia, Charlotte Niemeyer
-
Publication number: 20030125289Abstract: Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in the protein tyrosine phosphatase gene PTPN11 and its expression product, PTPN11, as well as mutations in other components in a PTPN11 signal transduction pathway promoting an increased signaling flux. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to PTPN11 and PTPN11 variants, and cells expressing such variants.Type: ApplicationFiled: October 1, 2002Publication date: July 3, 2003Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Bruce D. Gelb, Marco Tartaglia